Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

<br /> Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference<br />

PR Newswire

DUBLIN

,

Nov. 30, 2022

/PRNewswire/ —

Alkermes plc

(Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on

Wednesday, Dec. 7, 2022

at

8:00 a.m. ET

(

1:00 p.m. GMT

). The live webcast may be accessed under the Investors tab on

www.alkermes.com

and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at

www.alkermes.com

.

Contact:

Sandy Coombs

Investor Relations

+1 781 609 6377